OraSure Technologies Reports 2% Revenue Decrease to $30.6 Million in Q2 2026

OraSure Technologies, Inc. reported a decrease in consolidated net revenues for the second quarter of 2026, totaling $30.6 million, down 2% from $31.2 million in the same period last year. The decline was primarily attributed to a drop in revenues from its diagnostics products, which saw a slight increase to $19.4 million, driven by higher syphilis sales and the inclusion of revenues from the recently acquired BioMedomics, Inc. However, this was offset by lower revenues from HCV testing and domestic HIV sales. The company’s gross profit margin improved to 43.5%, up from 42.1% in the prior year, reflecting better operational efficiencies despite a negative product mix.

For the first half of 2026, OraSure's net revenues decreased by 4% to $58.6 million compared to $61.2 million in the same period of 2025. The decline in diagnostics product revenues was primarily due to reduced international HCV revenues and lower domestic HIV sales, which were partially offset by increased syphilis sales and contributions from the BioMedomics acquisition. The company reported an operating loss of $17.8 million for the six months ended June 30, 2026, an improvement from a loss of $35.8 million in the same period last year, largely due to a $22.5 million change in the estimated fair value of acquisition-related contingent consideration.

Significant operational changes included the discontinuation of the risk assessment testing product line, which contributed $1.9 million in revenues during the first half of 2025 but generated no revenue in 2026. The company also experienced a reduction in workforce as part of its restructuring efforts, which is expected to be completed by early 2027. As of June 30, 2026, OraSure's cash and cash equivalents stood at $160.6 million, down from $199.3 million at the end of 2025, with working capital also decreasing to $197.8 million.

In terms of strategic developments, OraSure received FDA clearance for its Colli-Pee™•Dx Urine Collection Kit in June 2026, which supports at-home self-collection for various tests. Additionally, the company received Emergency Use Authorization for its second-generation OraQuick™ Ebola Rapid Antigen Test in July 2026. These product launches are expected to enhance the company's market position and expand its diagnostic offerings.

Looking ahead, OraSure anticipates continued challenges in its revenue streams, particularly in the HCV and HIV segments, while also focusing on the successful commercialization of its new products. The company remains committed to improving operational efficiencies and managing costs effectively to navigate the evolving market landscape.